Korean J Transplant 2021; 35(1): 48-52
Published online March 31, 2021
https://doi.org/10.4285/kjt.20.0041
© The Korean Society for Transplantation
Phyo Wai Lwin1 , Yi Yi Htun2
, Aung Kyaw Myint3
, Htar Kyi Swe1
1Department of Nephrology, University of Medicine, Mandalay, Mandalay, Myanmar
2Department of Pharmacology, University of Medicine, Mandalay, Mandalay, Myanmar
3Department of Nephrology, Mandalay General Hospital, Mandalay, Myanmar
Correspondence to: Phyo Wai Lwin
Department of Nephrology, University of Medicine, Mandalay, Chan Aye Thar San Township, Mandalay Division, Myanmar
Tel: +95-9972349611
Fax: +95-9972349611
E-mail: lphyowai84@gmail.com
This is an Open Access article distributed under the terms of the Creative Commons Attribution Non-Commercial License (http://creativecommons.org/licenses/by-nc/4.0/) which permits unrestricted non-commercial use, distribution, and reproduction in any medium, provided the original work is properly cited.
Drug interactions between anti-tuberculosis and immunosuppressive medications after renal transplantation are a common problem in Myanmar. The efficacy of both types of drugs can be reduced during the treatment period, which can lead to graft failure and flare-ups of infection. Drug adjustments, with frequent monitoring and close follow-up, are crucial in this period. Ketoconazole decreases tacrolimus metabolism by inhibiting cytochrome P450-3A5 enzymes and P-glycoprotein. It is cost effective and has been frequently used to reduce the dose and cost of tacrolimus. Here, we report the case of a 56-year-old male renal transplant recipient with anti-tuberculosis medications.
Keywords: Post renal transplant tuberculosis, Immunosuppressant cost, Drug Interaction
HIGHLIGHTS |
---|
|
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |
![]() |